Zealand Pharma says Phase 2 ZUPREME-1 trial shows petrelintide cuts weight up to 10.7% at 42 weeks

Bitget2026/09/29 22:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zealand Pharma flagged Phase 2 ZUPREME-1 results for petrelintide in obesity, now published, with additional data due at EASD 2026.
Findings showed clinically meaningful weight loss with gastrointestinal tolerability broadly comparable to placebo, supporting patient persistence potential.
Study also indicated improvements in cardiometabolic risk markers, strengthening the drug’s profile beyond weight reduction.
Additional results will be presented on September 30, 2026 at 3:30 p.m. CEST in an EASD oral session.
A global Phase 3 registrational program for petrelintide monotherapy in chronic weight management has been initiated.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609291803PRIMZONEFULLFEED1001275299) on September 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zealand Pharma says Phase 2 ZUPREME-1 trial shows petrelintide cuts weight up to 10.7% at 42 weeks

You may also like

Crypto prices